MERTK and Hepatic fibrosis: The results of the aforementioned studies could leave room to a possible future role for the targeting of TAM receptors (e.g., with small molecule inhibitors against Axl or MERTK) as a therapeutic strategy for liver fibrosis management, with the caveat that any such therapeutic approach might face toxicity.